In Vitro Antibacterial Activity of Phx-3 against Helicobacter pylori

被引：13

作者：

Hanawa, Tomoko ^{[1
]}

Osaki, Takako ^{[1
]}

Manzoku, Taki ^{[4
]}

Fukuda, Minoru ^{[2
]}

Kawakami, Hayato ^{[3
]}

Tomoda, Akio ^{[5
]}

Kamiya, Shigeru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Infect Dis, Div Med Microbiol, Tokyo 1818611, Japan

[2] Kyorin Univ, Sch Med, Electron Microscopy Lab, Tokyo 1818611, Japan

[3] Kyorin Univ, Sch Med, Dept Biochem, Dept Anat 2, Tokyo 1818611, Japan

[4] Miyarisan Pharmaceut Co Ltd, Kita Ku, Tokyo 1140016, Japan

[5] Tokyo Med Univ, Shinjuku Ku, Tokyo 1608402, Japan

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2010年 / 33卷 / 02期

关键词：

Helicobacter pylori; phenoxazine; bactericidal agent; CLARITHROMYCIN; LANSOPRAZOLE; ANTIBIOTICS; ACTINOMYCIN; AMOXICILLIN; INHIBITION; POLIOVIRUS;

D O I：

10.1248/bpb.33.188

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Phx-3, one of the phenoxazine derivatives, is reported to have inhibitory effect on Mycobacterium species and Chlamydia pneumoniae but not Escherichia coli, Salmonella Typhimurium, Pseudomonas aeruginosa, Staphylococcus aureus, Listeria monocytogenes. The bactericidal activities of Phx-3 against Helicobacter pylori strains have not been assessed. Then, we measured minimum inhibitory concentration of Phx-3 for Helicobacter strains and assessed the morphological and biochemical effects of Phx-3 on H. pylori. In present study, it has shown that H. pylori strains including clarithromycin resistant strain and Helicobacter musterae were killed effectively by the treatment with Phx-3. Furthermore, severe morphological changes such as membrane blebbing and formation of hollows in H. pylori were detected. In addition, induction of heat shock protein 60 was observed. Taken together, Phx-3 has antibacterial activity against Helicobacter pylori.

引用

页码：188 / 191

页数：4

共 22 条

[1] Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome [J].

Adamek, RJ ;

Suerbaum, S ;

Pfaffenbach, B ;

Opferkuch, W .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :386-389

[2] In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657 [J].

Akada, JK ;

Shirai, M ;

Fujii, K ;

Okita, K ;

Nakazawa, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1072-1076

[3]

ANZAI K, 1960, J ANTIBIOT, V13, P125

[4] A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients [J].

Asaka, M ;

Sugiyama, T ;

Kato, M ;

Satoh, K ;

Kuwayama, H ;

Fukuda, Y ;

Fujioka, T ;

Takemoto, T ;

Kimura, K ;

Shimoyama, T ;

Shimizu, K ;

Kobayashi, S .

HELICOBACTER, 2001, 6 (03) :254-261

[5]

BENDIC C, 2006, INTERNET ELECT J MOL, V5, P320

[6] Helicobacter pylori uptake and efflux:: Basis for intrinsic susceptibility to antibiotics in vitro [J].

Bina, JE ;

Alm, RA ;

Uria-Nickelsen, M ;

Thomas, SR ;

Trust, TJ ;

Hancock, REW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :248-254

[7] ACTINOMYCINE .19. ANTIBIOTICA AUS ACTINOMYCETEN .40. KONSTITUTION UND SYNTHESE DES ACTINOMYCIN-CHROMOPHORS [J].

BROCKMANN, H ;

MUXFELDT, H .

CHEMISCHE BERICHTE-RECUEIL, 1958, 91 (06) :1242-1265

[8]

BUTENANDT A, 1960, PHYSIOL CHEM PHYS M, V319, P238

[9]

Clinical and Laboratory Standards Institute. (formerly NCCLS), 2000, METH DIL ANT SUSC TE

[10] ISOLATION AND CHARACTERIZATION OF A FAMILY OF PORIN PROTEINS FROM HELICOBACTER-PYLORI [J].

EXNER, MM ;

DOIG, P ;

TRUST, TJ ;

HANCOCK, REW .

INFECTION AND IMMUNITY, 1995, 63 (04) :1567-1572

← 1 2 3 →